Literature DB >> 19498407

Prostate cancer: WHO standardization of PSA tests: clinical consequences.

Carsten Stephan.   

Abstract

The introduction of WHO standards for PSA assays is a step forward for improving the comparability of these tests. our current clinical decision limits, however, were validated using traditional calibrators. The threshold for biopsy must be adjusted when using the new standards.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19498407     DOI： 10.1038/nrurol.2009.94

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  9 in total

1.  Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

Authors:  Carsten Stephan; Moritz Klaas; Christian Müller; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Journal:  Clin Chem       Date:  2006-01       Impact factor: 8.327

2.  Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994.

Authors:  T A Stamey
Journal:  Urology       Date:  1995-02       Impact factor: 2.649

3.  Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10)

Authors:  B Rafferty; P Rigsby; M Rose; T Stamey; R Gaines Das
Journal:  Clin Chem       Date:  2000-09       Impact factor: 8.327

4.  Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.

Authors:  F H Jansen; M Roobol; C H Bangma; R H N van Schaik
Journal:  Clin Chem       Date:  2008-10-16       Impact factor: 8.327

5.  Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

Authors:  Patricia R Slev; Sonia L La'ulu; William L Roberts
Journal:  Am J Clin Pathol       Date:  2008-06       Impact factor: 2.493

6.  Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.

Authors:  Carsten Stephan; Anna-Maria Kahrs; Silke Klotzek; Janett Reiche; Christian Müller; Michael Lein; Serdar Deger; Kurt Miller; Klaus Jung
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

7.  Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.

Authors:  Richard E Link; Shahrokh F Shariat; Cuong V Nguyen; Anita Farr; Armin D Weinberg; Ronald A Morton; Barbara Richardson; David Bernard; Kevin M Slawin
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.

Authors:  G Vignati; L Giovanelli
Journal:  Int J Biol Markers       Date:  2007 Oct-Dec       Impact factor: 3.248
  9 in total
  2 in total

1.  Variability of assay methods for total and free PSA after WHO standardization.

Authors:  L Foj; X Filella; J Alcover; J M Augé; J M Escudero; R Molina
Journal:  Tumour Biol       Date:  2013-10-04

2.  Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine.

Authors:  Juho Jasu; Teemu Tolonen; Emmanuel S Antonarakis; Himisha Beltran; Susan Halabi; Mario A Eisenberger; Michael A Carducci; Yohann Loriot; Kim Van der Eecken; Martijn Lolkema; Charles J Ryan; Sinja Taavitsainen; Silke Gillessen; Gunilla Högnäs; Timo Talvitie; Robert J Taylor; Antti Koskenalho; Piet Ost; Teemu J Murtola; Irina Rinta-Kiikka; Teuvo Tammela; Anssi Auvinen; Paula Kujala; Thomas J Smith; Pirkko-Liisa Kellokumpu-Lehtinen; William B Isaacs; Matti Nykter; Juha Kesseli; G Steven Bova
Journal:  Eur Urol Open Sci       Date:  2021-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.